Why is Mankind Pharma Ltd falling/rising?

Recent Price Movement and Market Context

Mankind Pharma’s share price has gained 5.88% over the past week, significantly outperforming the Sensex’s 1.00% rise during the same period. This marks a fifth consecutive day of gains, with the stock reaching an intraday high of ₹2,239.75, up 2.39% on the day. The stock’s current price sits above its 5-day and 20-day moving averages, signalling positive momentum in the near term. However, it remains below the 50-day, 100-day, and 200-day moving averages, indicating that the broader trend may still be under pressure.

Liquidity remains adequate, with the stock supporting a trade size of approximately ₹2.29 crore based on 2% of the five-day average traded value. Notably, investor participation has declined recently, with delivery volumes on 22 Dec falling by over 50% compared to the five-day average, suggesting some caution among market participants despite the price rise.

Fundamental Strengths Supporting the Stock

Mankind Pharma continues to demonstrate strong management efficiency, reflected in a high return on capital employed (ROCE) of 25.78%. This suggests the company is effective at generating profits from its capital base. Additionally, the firm maintains a conservative capital structure, with a low Debt to EBITDA ratio of 0.54 times, indicating a robust ability to service its debt obligations. Institutional investors hold nearly a quarter of the company’s shares (24.76%), which often signals confidence from sophisticated market participants who typically conduct thorough fundamental analysis.

Challenges Tempering Investor Optimism

Despite these positives, the company’s recent financial results have been underwhelming. For the nine months ending September 2025, interest expenses surged by 122.24% to ₹530.87 crore, while profit after tax (PAT) declined by 20.05% to ₹949.83 crore over the latest six-month period. The half-year ROCE has also dropped sharply to 12.33%, less than half the earlier figure, signalling a deterioration in capital efficiency.

Valuation concerns persist as well. With a ROCE of 11.7 and an enterprise value to capital employed ratio of 4.7, the stock is considered expensive relative to its peers’ historical averages. This is compounded by the stock’s poor returns over the past year, which stand at -25.69%, significantly lagging the Sensex’s 8.89% gain. Profitability has also contracted by 17.2% over the same period, highlighting operational pressures.

Longer-term performance has been disappointing, with the stock underperforming the BSE500 index across multiple time frames including one year, three years, and the last three months. This below-par performance reflects ongoing challenges in sustaining growth and investor confidence.

Conclusion: Why the Stock Is Rising Despite Headwinds

The recent rise in Mankind Pharma’s share price appears to be driven primarily by short-term technical momentum and relative outperformance against its sector and benchmark indices. The stock’s gains over the past week and its position above short-term moving averages suggest that traders are responding to positive price action and possibly to the company’s strong management efficiency and low leverage.

However, the fundamental backdrop remains mixed. While the company’s operational efficiency and debt servicing capacity are strengths, the decline in profitability, rising interest costs, and expensive valuation metrics weigh heavily on investor sentiment. The stock’s underperformance over the past year and longer term indicates that these challenges have not yet been fully resolved.

Investors should therefore approach the recent price rise with caution, recognising that it may reflect transient market dynamics rather than a sustained turnaround in the company’s financial health. Monitoring upcoming quarterly results and broader market conditions will be crucial to assess whether Mankind Pharma can translate its short-term momentum into longer-term value creation.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →